Which has higher earnings & valuation, QGEN or ILMN?

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.48 $424.88M $1.95 23.29 Illumina $4.34B 9.67 $850M $5.36 51.90

Is QGEN or ILMN more profitable?

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.49% 14.47% 8.34% Illumina 18.36% 29.84% 12.17%

Does the media favor QGEN or ILMN?

In the previous week, Illumina had 27 more articles in the media than Qiagen. MarketBeat recorded 29 mentions for Illumina and 2 mentions for Qiagen. Illumina's average media sentiment score of 0.72 beat Qiagen's score of 0.14 indicating that Illumina is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Illumina 9 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TMO or ILMN?

In the previous week, Thermo Fisher Scientific had 12 more articles in the media than Illumina. MarketBeat recorded 41 mentions for Thermo Fisher Scientific and 29 mentions for Illumina. Thermo Fisher Scientific's average media sentiment score of 1.18 beat Illumina's score of 0.72 indicating that Thermo Fisher Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Thermo Fisher Scientific 29 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Illumina 9 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, DHR or ILMN?

Danaher has higher revenue and earnings than Illumina. Danaher is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Danaher $25.11B 6.16 $3.61B $5.63 39.10 Illumina $4.34B 9.67 $850M $5.36 51.90

Is DHR or ILMN more profitable?

Illumina has a net margin of 18.36% compared to Danaher's net margin of 15.95%. Illumina's return on equity of 29.84% beat Danaher's return on equity. Company Net Margins Return on Equity Return on Assets Danaher 15.95% 11.04% 6.81% Illumina 18.36% 29.84% 12.17%

Does the media favor DHR or ILMN?

In the previous week, Danaher had 38 more articles in the media than Illumina. MarketBeat recorded 67 mentions for Danaher and 29 mentions for Illumina. Danaher's average media sentiment score of 1.45 beat Illumina's score of 0.72 indicating that Danaher is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Danaher 54 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Illumina 9 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ILMN or A?

In the previous week, Illumina had 24 more articles in the media than Agilent Technologies. MarketBeat recorded 29 mentions for Illumina and 5 mentions for Agilent Technologies. Illumina's average media sentiment score of 0.72 beat Agilent Technologies' score of 0.72 indicating that Illumina is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Illumina 9 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agilent Technologies 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, IQV or ILMN?

IQVIA has higher revenue and earnings than Illumina. IQVIA is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IQVIA $16.31B 2.63 $1.36B $8.06 32.29 Illumina $4.34B 9.67 $850M $5.36 51.90

Is IQV or ILMN more profitable?

Illumina has a net margin of 18.36% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Illumina's return on equity. Company Net Margins Return on Equity Return on Assets IQVIA 8.10% 30.25% 6.54% Illumina 18.36% 29.84% 12.17%

Does the media prefer IQV or ILMN?

In the previous week, Illumina had 21 more articles in the media than IQVIA. MarketBeat recorded 29 mentions for Illumina and 8 mentions for IQVIA. Illumina's average media sentiment score of 0.72 beat IQVIA's score of 0.44 indicating that Illumina is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Illumina 9 Very Positive mention(s) 6 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Illumina (ILMN) Competitors

$278.17 +13.60 (+5.14%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$278.54 +0.37 (+0.13%)

As of 10/9/2026 07:59 PM Eastern

Compare

ILMN vs. QGEN, TMO, DHR, A, and IQV

Should you buy Illumina stock or one of its competitors? Illumina's main competitors and comparable companies include Qiagen (QGEN), Thermo Fisher Scientific (TMO), Danaher (DHR), Agilent Technologies (A), and IQVIA (IQV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Illumina compare to Qiagen?

Qiagen (NYSE:QGEN) and Illumina (NASDAQ:ILMN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Qiagen currently has a consensus target price of $43.51, suggesting a potential downside of 4.22%. Illumina has a consensus target price of $222.19, suggesting a potential downside of 20.13%. Given Qiagen's higher probable upside, equities analysts plainly believe Qiagen is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44

Illumina has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.48	$424.88M	$1.95	23.29
Illumina	$4.34B	9.67	$850M	$5.36	51.90

Qiagen has a net margin of 19.49% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Illumina	18.36%	29.84%	12.17%

70.0% of Qiagen shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Illumina had 27 more articles in the media than Qiagen. MarketBeat recorded 29 mentions for Illumina and 2 mentions for Qiagen. Illumina's average media sentiment score of 0.72 beat Qiagen's score of 0.14 indicating that Illumina is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Illumina	9 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Illumina has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Summary

Illumina beats Qiagen on 13 of the 17 factors compared between the two stocks.

How does Illumina compare to Thermo Fisher Scientific?

Thermo Fisher Scientific (NYSE:TMO) and Illumina (NASDAQ:ILMN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Thermo Fisher Scientific currently has a consensus target price of $634.86, suggesting a potential downside of 3.55%. Illumina has a consensus target price of $222.19, suggesting a potential downside of 20.13%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, equities analysts plainly believe Thermo Fisher Scientific is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Thermo Fisher Scientific	2 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.80
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44

Thermo Fisher Scientific has higher revenue and earnings than Illumina. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Thermo Fisher Scientific	$44.56B	5.46	$6.70B	$18.59	35.41
Illumina	$4.34B	9.67	$850M	$5.36	51.90

Illumina has a net margin of 18.36% compared to Thermo Fisher Scientific's net margin of 15.04%. Illumina's return on equity of 29.84% beat Thermo Fisher Scientific's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Thermo Fisher Scientific	15.04%	17.09%	8.12%
Illumina	18.36%	29.84%	12.17%

89.2% of Thermo Fisher Scientific shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by company insiders. Comparatively, 2.9% of Illumina shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Thermo Fisher Scientific had 12 more articles in the media than Illumina. MarketBeat recorded 41 mentions for Thermo Fisher Scientific and 29 mentions for Illumina. Thermo Fisher Scientific's average media sentiment score of 1.18 beat Illumina's score of 0.72 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Thermo Fisher Scientific	29 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Illumina	9 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Thermo Fisher Scientific has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Illumina has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

Summary

Thermo Fisher Scientific beats Illumina on 9 of the 17 factors compared between the two stocks.

How does Illumina compare to Danaher?

Danaher (NYSE:DHR) and Illumina (NASDAQ:ILMN) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Danaher had 38 more articles in the media than Illumina. MarketBeat recorded 67 mentions for Danaher and 29 mentions for Illumina. Danaher's average media sentiment score of 1.45 beat Illumina's score of 0.72 indicating that Danaher is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Danaher	54 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Illumina	9 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Danaher has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Illumina has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Danaher has higher revenue and earnings than Illumina. Danaher is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Danaher	$25.11B	6.16	$3.61B	$5.63	39.10
Illumina	$4.34B	9.67	$850M	$5.36	51.90

79.1% of Danaher shares are held by institutional investors. Comparatively, 89.4% of Illumina shares are held by institutional investors. 10.8% of Danaher shares are held by insiders. Comparatively, 2.9% of Illumina shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Illumina has a net margin of 18.36% compared to Danaher's net margin of 15.95%. Illumina's return on equity of 29.84% beat Danaher's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Danaher	15.95%	11.04%	6.81%
Illumina	18.36%	29.84%	12.17%

Danaher presently has a consensus target price of $235.23, suggesting a potential upside of 6.85%. Illumina has a consensus target price of $222.19, suggesting a potential downside of 20.13%. Given Danaher's stronger consensus rating and higher probable upside, research analysts plainly believe Danaher is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Danaher	0 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Danaher beats Illumina on 10 of the 17 factors compared between the two stocks.

How does Illumina compare to Agilent Technologies?

Illumina (NASDAQ:ILMN) and Agilent Technologies (NYSE:A) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

Illumina currently has a consensus price target of $222.19, suggesting a potential downside of 20.13%. Agilent Technologies has a consensus price target of $171.82, suggesting a potential upside of 0.63%. Given Agilent Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Agilent Technologies is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.79

Agilent Technologies has higher revenue and earnings than Illumina. Agilent Technologies is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.34B	9.67	$850M	$5.36	51.90
Agilent Technologies	$6.95B	6.93	$1.30B	$5.08	33.61

Illumina has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Agilent Technologies has a net margin of 19.53% compared to Illumina's net margin of 18.36%. Illumina's return on equity of 29.84% beat Agilent Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
Agilent Technologies	19.53%	24.45%	13.09%

89.4% of Illumina shares are owned by institutional investors. 2.9% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Illumina had 24 more articles in the media than Agilent Technologies. MarketBeat recorded 29 mentions for Illumina and 5 mentions for Agilent Technologies. Illumina's average media sentiment score of 0.72 beat Agilent Technologies' score of 0.72 indicating that Illumina is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Illumina	9 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agilent Technologies	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Illumina beats Agilent Technologies on 9 of the 16 factors compared between the two stocks.

How does Illumina compare to IQVIA?

IQVIA (NYSE:IQV) and Illumina (NASDAQ:ILMN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 89.4% of Illumina shares are owned by institutional investors. 1.7% of IQVIA shares are owned by company insiders. Comparatively, 2.9% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

IQVIA has higher revenue and earnings than Illumina. IQVIA is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.63	$1.36B	$8.06	32.29
Illumina	$4.34B	9.67	$850M	$5.36	51.90

IQVIA has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Illumina has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Illumina has a net margin of 18.36% compared to IQVIA's net margin of 8.10%. IQVIA's return on equity of 30.25% beat Illumina's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Illumina	18.36%	29.84%	12.17%

IQVIA presently has a consensus price target of $274.31, indicating a potential upside of 5.40%. Illumina has a consensus price target of $222.19, indicating a potential downside of 20.13%. Given IQVIA's stronger consensus rating and higher probable upside, research analysts plainly believe IQVIA is more favorable than Illumina.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Illumina	2 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Illumina had 21 more articles in the media than IQVIA. MarketBeat recorded 29 mentions for Illumina and 8 mentions for IQVIA. Illumina's average media sentiment score of 0.72 beat IQVIA's score of 0.44 indicating that Illumina is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Illumina	9 Very Positive mention(s)	6 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IQVIA beats Illumina on 9 of the 17 factors compared between the two stocks.

Get Illumina News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ILMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ILMN vs. The Competition

Export

Metric	Illumina	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.00B	$10.72B	$7.26B	$13.29B
Dividend Yield	N/A	1.45%	2.52%	22.58%
P/E Ratio	51.90	32.42	275.28	26.14
Price / Sales	9.67	106.93	587.00	87.06
Price / Cash	41.43	27.28	27.30	36.12
Price / Book	15.61	6.48	10.82	6.16
Net Income	$850M	$56.67B	$3.50B	$381.12M
7 Day Performance	1.88%	-1.01%	-0.89%	-1.40%
1 Month Performance	34.74%	9.16%	-4.02%	-3.35%
1 Year Performance	196.37%	32.19%	7.13%	1.49%

Illumina Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ILMN Illumina	2.9231 of 5 stars	$278.17 +5.1%	$222.19 -20.1%	+196.4%	$42.00B	$4.34B	51.90	8,650	Analyst Forecast
QGEN Qiagen	2.6466 of 5 stars	$44.48 -1.2%	$43.51 -2.2%	-8.1%	$9.28B	$2.10B	22.79	5,500	High Trading Volume
TMO Thermo Fisher Scientific	4.0648 of 5 stars	$681.04 +0.4%	$628.78 -7.7%	+25.4%	$250.91B	$44.56B	36.63	125,000	News Coverage Positive News Analyst Forecast
DHR Danaher	4.1087 of 5 stars	$226.13 -0.5%	$230.23 +1.8%	+8.7%	$159.81B	$25.11B	40.16	60,000	News Coverage Positive News Analyst Forecast
A Agilent Technologies	3.5237 of 5 stars	$175.10 -0.1%	$170.33 -2.7%	+25.0%	$49.40B	$7.37B	34.47	18,100	Ex-Dividend Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ILMN) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Illumina (ILMN) Competitors